Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer

Hong Lin He, Ying En Lee, Hsin Pao Chen, Chung Hsi Hsing, I. Wei Chang, Yow Ling Shiue, Sung Wei Lee, Chao Tien Hsu, Li Ching Lin, Ting Feng Wu, Chien Feng Li

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Genes associated with protein folding have been found to have certain prognostic significance in a subset of cancers. The aim of this study is to evaluate the clinical impact of DNAJC12 expression in patients with rectal cancers receiving neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. Through data mining from a public transcriptomic dataset of rectal cancer focusing on genes associated with protein folding, we found that DNAJC12, a member of the HSP40/DNAJ family, was the most significant such gene correlated with the CCRT response. We further evaluated the expression of DNAJC12 by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancers. From this set, we statistically analyzed the association of DNAJC12 expression with various clinicopathological factors, tumor regression grade, overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS). High expression of DNAJC12 was significantly associated with advanced pre- and post-treatment tumor status (. P

Original languageEnglish
Pages (from-to)338-345
Number of pages8
JournalExperimental and Molecular Pathology
Volume98
Issue number3
DOIs
Publication statusPublished - Jun 1 2015
Externally publishedYes

    Fingerprint

Keywords

  • CCRT
  • Chemoradiotherapy
  • DNAJC12
  • HSP40
  • Rectal cancer

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

He, H. L., Lee, Y. E., Chen, H. P., Hsing, C. H., Chang, I. W., Shiue, Y. L., Lee, S. W., Hsu, C. T., Lin, L. C., Wu, T. F., & Li, C. F. (2015). Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Experimental and Molecular Pathology, 98(3), 338-345. https://doi.org/10.1016/j.yexmp.2015.03.029